Femara Lawyers

The manufacturer of a breast cancer drug, letrozole , is warning fertility doctors that it has been associated with birth defects , a caution prompted by reports that the drug was being used to help a woman become pregnant.

Letrozole is approved for use only in postmenopausal women with breast cancer. But there is evidence some doctors have prescribed it as a fertility treatment because it suppresses estrogen and can promote ovulation. It is marketed under the name Femara.

Swiss drug manufacturer Novartis is sending letters to fertility doctors worldwide to reiterate a warning that the drug should not be given to women who may be pregnant, said spokeswoman Kim Fox.

The U.S. label on the drug already warns that it has been associated with birth defects, but concerns arose when a researcher in Canada published a report noting cases where the drug had been given to pregnant women.

After the report, Novartis reviewed its safety database and found 13 reports of pregnant women receiving the drug worldwide, contrary to its warning label.

Of those 13, at least two had miscarriages and two had children with birth defects, Fox said. It was not clear how many of these women were given the drug to increase their fertility as opposed to some other reason.

Read More